Voyager Therapeutics (NASDAQ:VYGR) Coverage Initiated by Analysts at Cantor Fitzgerald

Analysts at Cantor Fitzgerald began coverage on shares of Voyager Therapeutics (NASDAQ:VYGR) in a research note issued on Friday,Briefing.com Automated Import reports. The brokerage set an “overweight” rating on the stock.

VYGR has been the subject of several other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a report on Thursday, November 14th. Citigroup began coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 target price on the stock. Wedbush started coverage on shares of Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price objective on the stock. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Finally, Leerink Partners assumed coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Voyager Therapeutics currently has an average rating of “Buy” and an average target price of $17.43.

Voyager Therapeutics Stock Performance

NASDAQ:VYGR traded down $0.13 during trading hours on Friday, hitting $5.60. The company’s stock had a trading volume of 81,802 shares, compared to its average volume of 316,990. The company has a market capitalization of $305.91 million, a PE ratio of 7.89 and a beta of 0.93. Voyager Therapeutics has a 52-week low of $5.19 and a 52-week high of $10.66. The business’s 50-day moving average is $6.15 and its two-hundred day moving average is $6.84.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million during the quarter, compared to the consensus estimate of $12.63 million. During the same period last year, the business posted ($0.59) EPS. As a group, analysts predict that Voyager Therapeutics will post -0.89 EPS for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the transaction, the chief operating officer now owns 112,328 shares in the company, valued at $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.53% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. lifted its stake in shares of Voyager Therapeutics by 14.5% in the second quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock worth $102,000 after acquiring an additional 1,630 shares in the last quarter. Hunter Perkins Capital Management LLC increased its holdings in Voyager Therapeutics by 3.3% during the 3rd quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock worth $375,000 after purchasing an additional 2,025 shares during the last quarter. Empowered Funds LLC raised its position in shares of Voyager Therapeutics by 5.4% in the 3rd quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after purchasing an additional 2,278 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Voyager Therapeutics by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 554,214 shares of the company’s stock valued at $4,384,000 after buying an additional 2,638 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of Voyager Therapeutics by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 137,477 shares of the company’s stock worth $804,000 after buying an additional 3,473 shares in the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.